BRIEF published on 10/26/2026 at 07:10, 2 days ago TME Pharma prolonge l'échéance de sa dette pour améliorer sa visibilité financière Valeur Actionnariale Stabilité Financière Échéance De La Dette Financement Par Obligations Licence NOX-A12
BRIEF published on 10/26/2026 at 07:10, 2 days ago TME Pharma Extends Debt Maturity to Enhance Financial Visibility Shareholder Value Debt Maturity Financial Stability Bond Financing NOX-A12 Licensing
PRESS RELEASE published on 10/26/2026 at 07:05, 2 days ago TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028
PRESS RELEASE published on 10/26/2026 at 07:05, 2 days ago TME Pharma extends financial visibility by lengthening debt maturity to June 2028
BRIEF published on 09/16/2026 at 08:05, 1 month 11 days ago TME Pharma NV's strategy and financial commitment Biotechnology Partnerships Financial Strategy TME Pharma NOX-A12
BRIEF published on 09/16/2026 at 08:05, 1 month 11 days ago Stratégie et engagement financier de TME Pharma N.V. Biotechnologie Stratégie Financière Partenariats TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 1 month 11 days ago MESSAGE DU CEO DE TME PHARMA TME Pharma publie une lettre aux actionnaires du CEO. Détails sur la stratégie financière, les partenariats pour le NOX-A12, la gestion du capital et les activités futures Stratégie Financière Partenariats CEO TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 1 month 11 days ago TME PHARMA CEO MESSAGE TME Pharma CEO message emphasizes strategic approach, financial discipline, and long-term value creation for shareholders. Updates on NOX-A12, cost-reduction strategy, and future plans CEO Message Financial Discipline TME Pharma Strategic Approach NOX-A12
BRIEF published on 08/24/2026 at 08:10, 2 months 3 days ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
BRIEF published on 08/24/2026 at 08:10, 2 months 3 days ago TME Pharma progresse vers des partenariats stratégiques pour la thérapie du cancer Glioblastome NOX-A12 Partenariats De Licence Tendances Du Marché Des Biotechnologies Transaction D'actions Du PDG
Published on 10/28/2026 at 02:55, 4 hours 47 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 4 hours 52 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 8 hours 2 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 8 hours 17 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/27/2026 at 21:30, 10 hours 12 minutes ago Apex Announces Closing of Over-Allotment Option
Published on 10/28/2026 at 07:32, 10 minutes ago Correction: PALFINGER sharpens portfolio and risk profile, strengthening focus, profitability and resilience in the third quarter 2026
Published on 10/28/2026 at 07:30, 12 minutes ago Media Release: Sensirion announces global availability of the single-use SFM3304-D for proximal flow measurement in mechanical ventilation
Published on 10/28/2026 at 07:30, 12 minutes ago Delivery Hero hits one billion orders in Q3 as growth accelerates further, raises full-year guidance
Published on 10/28/2026 at 07:30, 12 minutes ago Symrise delivered strong volume-driven organic sales growth in Q3 2026 and reaffirms full-year outlook
Published on 10/28/2026 at 07:08, 34 minutes ago EEII AG: EEII AG et Haute Capital Partners SA signent une déclaration d’intention commune non contraignante
Published on 10/27/2026 at 18:00, 13 hours 42 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 13 hours 42 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
